Zimycan NDA
This article was originally published in The Tan Sheet
Executive Summary
Barrier Therapeutics expects a first-action letter from FDA relating to approval of its prescription Zimycan ointment for diaper dermatitis complicated by candidiasis during the first half of 2005, and is gearing up for potential launch in the second half, according to Chief Commercial Officer Al Altomari. Barrier acquired rights for the product in a 2002 licensing agreement with J&J, following a failed attempt to gain OTC clearance (1"The Tan Sheet" Aug. 16, 2004, p. 9). Barrier recently submitted results of a Phase III trial showing significant efficacy superiority versus vehicle in an amendment to its NDA...
You may also be interested in...
OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial
Barrier Therapeutics plans to parlay Johnson & Johnson's failed over-the-counter diaper cream Zimycan into the first prescription treatment for diaper rash complicated by Candida yeast infection
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.